David Raben
Impact in
- Otorhinolaryngology top 0.02%
- Head and Neck Cancer Studies
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
Papers in
-
- Head and Neck Cancer Studies 63
- Oncology 74
- Cancer Immunotherapy and Biomarkers 15
- HER2/EGFR in Cancer Research 9
- Co-authors
- Robert Louis Ferris (3 shared papers)Michalis V. Karamouzis (1 shared paper)Athanassios E. Argiris (1 shared paper)Paul M. Harari (13 shared papers)James A. Bonner (12 shared papers)Jordi Giralt López de Sagredo (9 shared papers)Christopher Uwe Jones (4 shared papers)José Baselga (4 shared papers)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (48 papers)Clinical Cancer Research (15 papers)Cancer (8 papers)Journal of Clinical Oncology (6 papers)Annals of Oncology (6 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
David Raben
224 papers receiving 18.0k citations
David Raben's Hit Papers
Peers
Comparison fields: 5 of 151
- Otorhinolaryngology 5.4k
- Oncology 5.8k
- Pulmonary and Respiratory Medicine 5.0k
- Cancer Research 1.7k
- Radiation 590
Countries citing papers authored by David Raben
This map shows the geographic impact of David Raben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Raben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Raben more than expected).
Fields of papers citing papers by David Raben
This network shows the impact of papers produced by David Raben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Raben. The network helps show where David Raben may publish in the future.
Co-authors
The 25 scholars most cited alongside David Raben, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 229 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2006 | 4141 |
| 2 | Head and neck cancer Hit paper breakdown → | 2008 | 1954 |
| 3 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Hit paper breakdown → | 2009 | 1563 |
| 4 | Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy Hit paper breakdown → | 2011 | 755 |
| 5 | Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study Hit paper breakdown → | 2016 | 581 |
| 6 | Prostate Cancer, Version 1.2016 Hit paper breakdown → | 2016 | 568 |
| 7 | p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma Hit paper breakdown → | 2014 | 325 |
| 8 | Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. | 1998 | 310 |
| 9 | 2014 | 284 | |
| 10 | 2007 | 237 | |
| 11 | 2018 | 231 | |
| 12 | Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). | 2002 | 213 |
| 13 | 2018 | 213 | |
| 14 | 2005 | 205 | |
| 15 | 2015 | 178 | |
| 16 | 2006 | 173 | |
| 17 | 2020 | 170 | |
| 18 | 2007 | 164 | |
| 19 | 2014 | 158 | |
| 20 | 2011 | 139 |
About David Raben
David Raben is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging, having authored 229 papers that have together received 18.6k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (63 papers), Lung Cancer Treatments and Mutations (34 papers), Prostate Cancer Diagnosis and Treatment (21 papers), Advanced Radiotherapy Techniques (16 papers), Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Diagnosis and Treatment (13 papers), Colorectal and Anal Carcinomas (11 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Otorhinolaryngology (5.4k citations), Oncology (5.8k citations), Pulmonary and Respiratory Medicine (5.0k citations), Cancer Research (1.7k citations) and Radiation (590 citations). David Raben has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Robert Louis Ferris, Michalis V. Karamouzis, Athanassios E. Argiris, Paul M. Harari, James A. Bonner, Jordi Giralt López de Sagredo, Christopher Uwe Jones, José Baselga, Roger B. Cohen and Ranjan Kumar Sur. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Clinical Cancer Research, Cancer, Journal of Clinical Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.